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Abstract
Carvedilol, a non-selective b-adrenoreceptor blocker, has been shown to possess a high degree of cardioprotection in experimental
models of myocardial damage. Reactive oxygen species have been proposed to be implicated in such situations, and antioxidants have been
demonstrated to provide partial protection to the reported damage. The purpose of our study was to investigate the antioxidant effect of
carvedilol and its metabolite BM-910228 by measuring the extent of lipid peroxidation in a model of severe oxidative damage induced by
ADP/FeSO4 in isolated rat heart mitochondria. Carvedilol and BM-910228 inhibited the thiobarbituric acid-reactive substance formation and
oxygen consumption associated with lipid peroxidation with IC50 values of 6 and 0.22 mM, respectively. Under the same conditions, the IC50
values of a-tocopheryl succinate and Trolox were 125 and 31 mM, respectively. As expected, the presence of carvedilol and BM-910228
preserved the structural and functional integrity of mitochondria under oxidative stress conditions for the same concentration range shown
to inhibit lipid peroxidation, since they prevented the collapse of the mitochondrial membrane potential (DC) induced by ADP/FeSO4 in
respiring mitochondria. It should be stressed that neither carvedilol nor BM-910228 induced any toxic effect on mitochondrial function in
the concentration range of the compounds that inhibits the peroxidation of mitochondrial membranes. In conclusion, the antioxidant
properties of carvedilol may contribute to the cardioprotective effects of the compound, namely through the preservation of mitochondrial
functions whose importance in myocardial dysfunction is clearly documented. Additionally, its hydroxylated analog BM-910220, with its
notably superior antioxidant activity, may significantly contribute to the therapeutic effects of carvedilol. © 2001 Elsevier Science Inc. All
rights reserved.
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1. Introduction
Carvedilol (Kredex®, Coreg®, Dibloc®; 1-(9H-carbazol-
4-yloxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol)
(Fig. 1) is an antihypertensive agent with multiple pharma-
cological properties of non-selective b-adrenergic antago-
nism with vasodilating properties exerted primarily through
selective a1-blockade [1]. Carvedilol also has potent anti-
oxidant action [2–5] as a superoxide and hydroxyl radical
scavenger [3,6], and its chain-breaking activity suggests that
it is an efficient and powerful biological antioxidant [4].
Recent studies have demonstrated a beneficial role of carve-
dilol in the management of controlled congestive heart fail-
ure as well as of ischemic symptoms associated with stable
and unstable angina pectoris [1]. The mechanisms underly-
ing the multiple cardioprotective effects of carvedilol are
not fully understood. However, its antioxidant activity is
most likely responsible for its well-documented superior
cardioprotection relative to typical b-blockers [1,7].
Substantial evidence supports the involvement of ROS in
myocardial damage during ischemic insult [8] and espe-
cially during reperfusion that brings about additional dam-
age [9–11]; these deleterious effects associated with isch-
emia/reperfusion conditions were shown to be minimized
by antioxidant compounds [12]. The mitochondrial respira-
tory chain has long been recognized as a major endogenous
source of ROS [13–15]. It has been estimated that during
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normal metabolism, 1–2% of oxygen reacting with the re-
spiratory chain leads to the formation of superoxide radicals
[16,17]. Under normal physiological conditions, mitochon-
drial antioxidant systems (enzymatic and non-enzymatic)
scavenge free radicals and preserve mitochondrial integrity
[18]; however, under certain pathophysiological conditions
such as myocardial ischemia and especially during reperfu-
sion [19,20], mitochondrial O2z2/H2O2 generation dramati-
cally increases [15,21]. The presence of polyunsaturated
fatty acid-rich membranes enhances mitochondrial suscep-
tibility to lipid peroxidation that can lead to membrane
dysfunction and alterations in the structural and functional
integrity of mitochondria, making these organelles potential
contributors to ischemic and reperfusion injury [22,23]. In
fact, previous studies showed that ROS are implicated in
deleterious actions on mitochondrial structure and function
that contribute to alterations of cardiac function [24]. Con-
sequently, the antioxidant action of carvedilol and its hy-
droxylated metabolite BM-910228, which has been shown
to possess superior antioxidant action compared to the par-
ent compound [25], may contribute to the preservation of
mitochondrial function, thus protecting myocardium from
energy depletion under oxidative stress conditions.
The present study was undertaken to assess the in vitro
antioxidant properties of carvedilol and its metabolite BM-
910228 on lipid peroxidation initiated by ADP plus Fe21 in
isolated rat heart mitochondria. Additionally, the direct ac-
tion of the compounds on mitochondrial bioenergetics was
assessed for the purpose of clarifying whether the antioxi-
dant doses of the compounds exhibit any mitochondrial
toxicity so as to validate their therapeutic relevance.
2. Material and methods
2.1. Preparation of heart mitochondria
Heart mitochondria were prepared from adult Wistar
strain rats (200–300 g) by conventional methods [26], with
slight modifications. Rats were killed by cervical disloca-
tion followed by decapitation, and the heart (1.0–1.5 g) was
immediately excised and finely minced with a pair of sharp
dissecting scissors in an ice-cold isolation medium contain-
ing 250 mM sucrose, 0.5 mM EGTA, 10 mM HEPES-KOH,
pH 7.4. The minced blood-free tissue was then resuspended
in 20 mL of isolation medium containing 0.1% (w/v) de-
fatted bovine serum albumin (BSA; Sigma Chemical No.
A-7030) and transferred to a 50-mL glass homogenizer
vessel containing 20 mL of isolation medium supplemented
with 0.5 mg of protease Type VIII (Sigma Chemical No.
P-5390) per g of tissue and homogenized with a tightly
fitted Potter–Elvehjen homogenizer. The suspension was
incubated for 1 min (4°) and then rehomogenized. The
homogenate was then centrifuged at 10,000 g for 10 min
(Sorvall RC-5C, Plus, SS34 rotor, 4°). The supernatant fluid
was decanted and the pellet, essentially devoid of protease,
was gently homogenized to its original volume with a loose-
fitting homogenizer. The suspension was centrifuged at 500
g for 10 min and the resulting supernatant was centrifuged
at 10,000 g for 10 min. The pellet was resuspended using
a paint brush and repelleted twice at 10,000 g for 10 min.
EGTA and defatted BSA were omitted from the final wash-
ing medium. All mitochondrial isolation procedures were
performed at 0–4°. For lipid peroxidation assays, the mi-
tochondrial pellet was pelleted in a buffer consisting of 175
mM KCl, 10 mM Tris, pH 7.4, in order to remove sucrose
(which may interfere with the thiobarbituric acid reaction).
After isolation, the mitochondrial suspension was used after
a 20-min recovery and within 4 hr. The isolation procedure
yielded well-coupled mitochondria: the respiratory control
ratio of the heart mitochondria varied from 8–10 (malate–
glutamate as substrate) or 3–4 (succinate as substrate).
Mitochondrial protein was determined by the biuret method
[27], using BSA as standard.
2.2. Induction and assay of lipid peroxidation
Lipid peroxidation in rat heart mitochondria was mea-
sured as described by Sassa et al. [28] by monitoring, at 25°,
the oxygen consumption with a Clark oxygen electrode of 1
mg mitochondria in a total volume of 1 mL of a medium
consisting of 175 mM KCl, 10 mM Tris–HCl, pH 7.4,
supplemented with 3 mM rotenone. Peroxidation was
started by adding final concentrations of 1 mM ADP and 0.1
mM FeSO4 after a 2-min incubation period. The saturated
concentration of O2 in the incubation medium was assumed
to be 238 mM at 25°.
Lipid peroxidation was also measured by determining
the amount of lipid peroxides formed during incubation as
Fig. 1. Chemical structures of carvedilol 1-(9H-carbazol-4-yloxy]-3-[[2-
(2-methoxyphenoxy)ethyl]amino]-2-propanol and BM-910228 (4-[2-hy-
droxyl-3-[[2-(2-methoxyphenoxy)ethyl]amino]propoxyl]-9H-carbazol-3-
ol]. BM-910228, one of the main metabolites of carvedilol, differs from
carvedilol in being hydroxylated at position 3 of the carbazole group.
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the amount of TBARS formed according to Rohn et al. [29],
with some modifications. Mitochondrial protein (3 mg) was
incubated at 25° in 3 mL of a medium consisting of 175 mM
KCl, 10 mM Tris, pH 7.4, supplemented with 3 mM rote-
none. The drugs (carvedilol and BM-910228) were allowed
to incubate for 2 min before membrane lipid peroxidation
was started by simultaneously adding ADP/FeSO4 (1 mM/
0.1 mM). At selected time intervals, samples of 0.3 mL
were taken and mixed with 2.7 mL of a TBARS reagent
consisting of 9% thiobarbituric acid (TBA), 0.6 N HCl, and
0.0056% 2,6-diterbutyl-4-methylphenol (BHT). The mix-
ture was heated at 80–90° for 15 min and recooled in ice for
10 min before centrifugation in an Eppendorf centrifuge
(1500 g, 5 min). Lipid peroxidation was estimated by the
appearance of TBARS spectrophotometrically quantified at
535 nm. The amount of TBARS formed was calculated
using a molar extinction coefficient of 1.56 3 105 M21
cm21 and expressed as nmol TBARS/mg protein [30].
2.3. Oxygen consumption assays
Oxygen consumption was analyzed polarographically, at
25°, using a YSI Biological Oxygen Monitor (model 5300)
and a Clark-type oxygen electrode (model 5331; Yellow
Springs Instrument Co. Inc.) connected to a Kipp & Zonen
chart recorder. Reactions were conducted in a 1-mL ther-
mostatically closed and magnetically stirred glass vessel
containing 1 mg of mitochondria in a respiration buffer of
130 mM sucrose, 50 mM KCl, 2.5 mM KH2PO4, 5 mM
HEPES, pH 7.4, supplemented with 3 mM rotenone. After a
2-min incubation period, mitochondrial respiration was ini-
tiated by addition of 8 mM succinate. Respiratory states
were as defined by Chance and Williams [31]. State 3 rates
were measured after the addition of 8 mM succinate and
0.25 mM ADP; state 4 rates were measured as the rates of
oxygen consumption after exhaustion of ADP. Respiratory
control ratios (RCR 5 state 3/state 4 rate), used to assess
functional integrity, and ADP/O ratios were determined
according to Estabrook [32]. The scale of oxygen uptake
was calibrated according to the oxygen consumed by sub-
mitochondrial particles after the addition of titrated solu-
tions of NADH.
In order to examine the effects of the drugs on mitochon-
drial respiration, we added the respiratory substrates after an
incubation period of 2 min. Drugs were prepared in absolute
ethanol. Concentration of ethanol in the assay medium was
less than 0.2%, the concentration also used in the controls.
2.4. Mitochondrial membrane potential (DC)
measurements
The mitochondrial membrane potential (DC) was esti-
mated by continuously monitoring the accumulation and
release of the lipophilic cation TPP1 with a TPP1-sensitive
electrode prepared in our laboratory, according to Kamo et
al. [33]. Therefore, the calculated DC values were uncor-
rected for possible volume changes induced by the com-
pounds tested. A mini-electrode was constructed with a
poly(vinyl chloride) tube sealed with a poly(vinyl chloride)-
based membrane containing the tetraphenylboron ion
(TPB2) as a cation exchanger and filled with a 10 mM
TPP1 solution. The reference electrode was an Ag/AgCl-
saturated electrode (Tacussel, Model MI 402). Both the
TPP1 and the reference electrode were inserted into the
chamber used for determination of mitochondrial oxygen
consumption and were connected to a pH meter (Radiom-
eter, Model PHM 84). The signals were simultaneously fed
to a dual-trace potentiometric recorder (Kipp & Zonen,
Model BD 112). Mitochondria were incubated in the reac-
tion medium containing 3 mM TPP1. This TPP1 concen-
tration was chosen to achieve high sensitivity in measure-
ments and to avoid possible toxic effects on mitochondria.
The transmembrane electric potential was estimated from
the following equation (at 25°), assuming that the TPP1
distribution between mitochondria and the medium follows
the Nernst equation, as previously described [33]:
DC (mV) 5 59 log (v/V) 2 59 log (10DE/59 2 1)
where v, V, and DE stand for mitochondrial volume, volume
of the incubation medium, and the deflection of the elec-
trode potential from the baseline, respectively. No correc-
tion was made for the “passive” binding contribution of
TPP1 to the mitochondrial membranes, because the purpose
of the experiments was to show relative changes in potential
rather than absolute values. Drugs were added in ethanolic
solutions to the reaction medium supplemented with mito-
chondria and allowed to incubate for 2 min before the
addition of the respiratory substrate or ADP/Fe21. Neither
carvedilol nor its metabolite affected TPP1 binding to mi-
tochondrial membranes or the electrode response. Calcula-
tions of the transmembrane potential were based on a matrix
volume of 1.1 mL/mg protein [34]. The lipid peroxidation
effect on DC induced by ADP/Fe21 was carried out as
previously described for DC determination using the respi-
ratory medium supplemented with 1.0 mg oligomycin as
reaction medium to prevent any depolarization associated
with phosphorylation that might follow the addition of
ADP/Fe21.
2.5. Statistical analysis
Results are presented as means 6 SEM for the number of
experiments indicated in the legends to the figures. Statis-
tical evaluation was performed using the two-tailed Stu-
dent’s t-test; differences with a value of P , 0.05 were
considered significant.
2.6. Calculation of IC50 values
The protective activity of the drugs tested was calculated
as percent inhibition of TBARS formation obtained in the
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absence of the inhibitor (assumed to be 100%). We deter-
mined IC50 values by using the GraphPad Prism program,
version 2.0, distributed by GraphPad Software, Inc.
2.7. Chemicals
Carvedilol and BM-910228 were obtained from Boehr-
inger Mannheim and used in ethanolic solutions. Other
reagents were of the highest grade commercially available.
3. Results
In this study, we examined the antioxidant effect of
carvedilol and its hydroxylated analog BM-910228 by mea-
suring the extent of lipid peroxidation in a model of severe
oxidative damage induced by ADP (1 mM)/FeSO4 (0.1
mM) in isolated non-energized rat heart mitochondria. For
comparison, we also examined the effects of the well-
known antilipid peroxidation reagents a-tocopherol and
Trolox [35]. First, we carried out the quantitative evaluation
of their antiperoxidation effects on mitochondrial mem-
branes in terms of TBARS formation induced by ADP/Fe21
(Fig. 2). Clearly, carvedilol and BM-910228 dose-depen-
dently inhibited ADP/Fe21-induced lipid peroxidation in
heart mitochondria. To confirm the clear antioxidant effects
of the test compounds observed by use of the TBARS assay,
we monitored the time-dependent change in the peroxida-
tion-related oxygen concentration of the rat heart mitochon-
drial suspension. As shown in Fig. 3, slow oxygen con-
sumption was observed for a few minutes after the addition
of ADP/Fe21, after which the consumption of oxygen in-
creased dramatically (Fig. 3, trace 0 mM). The time associ-
ated with the slow oxygen consumption that followed the
addition of ADP/Fe21 until the rapid oxygen uptake (lag
time) is regarded to be the time required for the generation
of a sufficient amount of ROS derived from ADP/Fe21,
such as the perferryl complex ADP-Fe31-O2z2, responsible
for the induction of lipid peroxidation [28,36,37]; the rapid
oxygen consumption after this lag phase follows the per-
oxidative radical chain proliferation of membrane lipids by
ROS. The extent of rapid oxygen consumption can be re-
garded as a good index of lipid peroxidation, seeing that it
correlates well with the amount of TBARS formed from
peroxide of fatty acid chains of mitochondrial phospholipids
with TBARS [38].
The ability of the test compounds to inhibit lipid peroxi-
dation in rat heart mitochondria was compared, as shown in
Fig. 4. Carvedilol and BM-910228 dose-dependently inhib-
ited ADP/Fe21-induced lipid peroxidation. The concentra-
tion for 50% inhibition of the peroxidation (IC50 values), as
summarized in Fig. 4, decreased in the order BM-910228 .
carvedilol . a-tocopheryl succinate . Trolox. The IC50
values of carvedilol and BM-910228 were 6 and 0.22 mM,
Fig. 2. Amounts of TBARS formed during lipid peroxidation in rat heart membranes induced by ADP/Fe21 (1 mM/0.1 mM). Rat heart mitochondria (1 mg)
were incubated in 1 mL of medium consisting of 175 mM KCl, 10 mM Tris (pH 7.4) supplemented with 3 mM rotenone at 25° for 2 min. Peroxidation was
started by adding 1 mM ADP and 0.1 mM FeSO4. Data are means 6 SEM of 4–5 experiments, each done in duplicate.
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respectively. Under the same conditions, the IC50 values of
a-tocopheryl succinate and Trolox were 125 and 31 mM,
respectively. It is noteworthy that the IC50 values were the
same independently of the method used, i.e. the TBARS
method or oxygen uptake. Carvedilol and especially BM-
910228 were found to be much more potent antiperoxida-
tion reagents than a-tocopheryl succinate and Trolox.
The energetic efficiency of the respiratory chain is
clearly linked to the intactness of the inner mitochondrial
membrane and to its impermeability to protons [38]. It is
generally accepted that lipid peroxidation processes disturb
mitochondrial energetic efficiency. In fact, it was demon-
strated that lipid peroxidation of mitochondrial membranes
correlates with changes in membrane integrity, causing their
irreversible swelling, disruption, and the efflux of cations
from the mitochondria [39]. The mitochondrial functions
strictly depend on the maintenance of the proton motive
force (Dp) generated by respiration. Any condition that
brings about a disruption of the inner mitochondrial mem-
brane will cause the collapse of Dp. Since DC is the main
component of the Dp, it was of interest to monitor the drop
in DC that follows membrane disruption linked to lipid
peroxidation induced by oxidative stress. Fig. 5 shows the
development of DC after mitochondrial energization with
succinate. In this experiment, the energization of mitochon-
dria was carried out in the presence of oligomycin, a specific
inhibitor of mitochondrial ATP synthase, in an attempt to
avoid the membrane depolarization that follows upon addi-
Fig. 3. Effects of carvedilol, BM-910228, Trolox, and a-tocopheryl succinate on O2 consumption due to lipid peroxidation of isolated rat heart mitochondrial
membranes induced by ADP and Fe21. Rat heart mitochondria (1 mg) were incubated in 1 mL of medium consisting of 175 mM KCl, 10 mM Tris (pH 7.4)
at 25°, supplemented with 3 mM rotenone. Peroxidation was started by adding 1 mM ADP and 0.1 mM FeSO4. Numerical values adjacent to traces indicate
concentrations of drugs in mM. The traces represent typical recordings from several (4–5) experiments, each performed in duplicate.
Fig. 4. (A) Concentration dependence of antiperoxidative activities of
carvedilol, BM-910228, Trolox, and a-tocopheryl succinate in rat heart
mitochondria. Antiperoxidative activity, shown as % control, was taken
from the results of Fig. 2. (B) The IC50 values for the different compounds
calculated from A.
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tion of ADP/Fe21. Fig. 5 shows that under succinate ener-
gization, mitochondria built up and sustained for more than
60 min, a DC close to 2205 mV when ADP/Fe21 was
absent. After the addition of ADP/Fe21, a lag phase fol-
lowed that represents the time required for the generation of
a sufficient amount of ROS responsible for the initiation of
lipid peroxidation; the potential underwent a rapid decline
after this lag phase. This decline in the DC represents the
disruption of mitochondrial membrane promoted by lipid
peroxidation. Carvedilol and BM-910228 exhibited a dose-
dependent, clear-cut protection against the collapse of DC
promoted by ROS. It is important to note that the maximum
protection of the drugs afforded DC was attained in the
concentration range of 10 mM of carvedilol and 0.5 mM of
BM-910228, i.e., the drug concentrations showing maxi-
mum antioxidant capabilities as determined by the quanti-
fication of TBARS and the monitoring of oxygen consump-
tion. The stabilizing action of the drugs on mitochondrial
inner membrane preserves the capability of mitochondria to
participate in energy-linked processes such as oxidative
phosphorylation under noxious conditions such as those
associated with oxidative stress.
It is noteworthy that carvedilol and BM-910228 did not
affect mitochondrial function in the concentration range
showing both electric potential preservation and antiperoxi-
dation action. In fact, the drugs did not affect either the
respiratory control ratio (RCR) or the phosphorylation index
(ADP/O ratio) of heart mitochondria, suggesting a protec-
tive action on the structural and functional capability of
mitochondria (Table 1).
In order to further confirm the non-toxic nature of carve-
dilol and BM-910228 on heart mitochondria, we measured
the DC fluctuations associated with mitochondrial respira-
tion and the phosphorylation cycle induced by ADP. Fig. 6
shows that control mitochondria, upon the addition of suc-
cinate, developed a DC close to 2200 mV (state 4 condi-
tion). Addition of ADP caused an immediate fall to 2170
mV (state 3 condition), a decrease that corresponds to the
Fig. 5. Effect of carvedilol and BM-910228 on the mitochondrial transmembrane potential (DC) decrease induced by ADP and Fe21. Rat heart mitochondria
(1 mg) were incubated in 1 mL of medium consisting of 130 mM sucrose, 50 mM KCl, 2.5 mM KH2PO4, 5 mM HEPES (pH 7.4), at 25° supplemented with
1 mg oligomycin, 3 mM rotenone, and 3 mM TPP1. After succinate (8 mM) energization (2–3 min) in the absence (control) or presence of increasing
concentrations of drugs, peroxidation was started by adding 1 mM ADP and 0.1 mM FeSO4. Concentration (in mM) of tested compounds is shown beside
traces. The traces represent typical recordings from several (4–5) experiments, each performed in duplicate.
Table 1
Effects of carvedilol and BM-910228 on heart mitochondrial respiratory parameters RCR (respiratory control ratio) and ADP/O
Carvedilol
(mM)
Effect of carvedilol on BM-910228
(mM)
Effect of BM-910228 on
RCR ADP/O RCR ADP/O
0.0 3.23 6 0.05 1.55 6 0.04 0.0 3.23 6 0.05 1.55 6 0.04
1.0 3.28 6 0.10 1.58 6 0.05 0.05 3.10 6 0.08 1.58 6 0.04
2.0 3.20 6 0.14 1.61 6 0.04 0.1 3.10 6 0.08 1.59 6 0.03
4.0 3.30 6 0.25 1.59 6 0.04 0.2 3.15 6 0.11 1.59 6 0.04
6.0 3.38 6 0.15 1.60 6 0.02 0.3 3.13 6 0.10 1.59 6 0.02
8.0 3.13 6 0.19 1.60 6 0.03 0.4 3.18 6 0.01 1.61 6 0.03
10.0 3.13 6 0.05 1.61 6 0.05 0.5 3.20 6 0.08 1.60 6 0.03
Rat heart mitochondria (1 mg) incubated in 1 mL of medium consisting of 130 mM sucrose, 50 mM KCl, 2.5 mM KH2PO4, 5 mM HEPES (pH 7.4), at
25°, supplemented with 3 mM rotenone, were energized with 8 mM succinate to induce state 4 respiration. State 3 respiration was initiated by adding 0.25
mM ADP. Data are means 6 SEM of 4–5 experiments, each performed in duplicate.
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energy utilized for ATP synthesis. When the phosphoryla-
tion cycle was completed (after a lag phase of about 1 min),
the DC almost returned to its initial value. BM-910228, in
the concentration range 0.1–0.5 mM, did not affect either
the energization by succinate or the DC fluctuations linked
to the phosphorylation cycle, confirming that the drug does
not affect either the respiratory chain or the phosphorylation
system of mitochondria. Higher concentrations of
BM-910228, in the range of 10 mM, did not affect mito-
chondrial function (data not shown). As opposed to BM-
910228, carvedilol, although it did not affect the DC fluc-
tuations associated with the phosphorylation cycle, did
show a slight depressive effect on the DC generated by
mitochondrial respiration; carvedilol consistently decreased
the DC, which declined only about 8 mV for the maximum
concentration of carvedilol used (10 mM). Furthermore, the
depolarization induced by ADP in the presence of 10 mM
carvedilol was only 25 mV compared to the value of 34 mV
in the control. Nevertheless, carvedilol did not alter the
phosphorylation efficiency of heart mitochondria, since the
ADP/O ratios were not affected by the presence of the
compound.
The non-toxic effect of carvedilol on mitochondria was
further confirmed by monitoring the pH changes associated
with mitochondrial ATP synthesis. Carvedilol even at
higher concentrations (up to 20 mM), much higher than
those shown to inhibit mitochondrial lipid peroxidation,
failed to induce adverse effects on mitochondrial ATP syn-
thase, since both the rate and amplitude of pH changes
linked to ATP synthesis were not affected (data not shown).
Furthermore, ATPase activity of bovine heart submitochon-
drial particles, as assessed by monitoring the pH decrease
linked to ATP hydrolysis, was not affected by high concen-
trations of carvedilol (up to 40 mM), further confirming the
non-adverse effects on mitochondrial ATP synthase/AT-
Pase (data not shown).
4. Discussion
It is well known that mitochondria are very sensitive to
oxidative stress conditions [40], which explains the reported
impairment of mitochondrial functions associated with
pathological conditions such as ischemia and reperfusion
[41,42]. To highlight the importance of carvedilol and its
metabolite BM-910228 in the protection of mitochondria
from oxidative stress conditions, we examined their effect
on ADP/Fe21-induced lipid peroxidation of rat heart mito-
chondrial membranes. With this system, active oxygen spe-
cies chelated with Fe31 and ADP such as the ADP-Fe31-
O2z2 complex are thought to be initiators of radical chain
reactions [43].
Our study showed that both carvedilol and BM-910228
have potent antiperoxidative effects on heart mitochondrial
membranes. The IC50 values for carvedilol (6 mM) and
BM-910228 (0.22 mM) found for rat heart mitochondrial
membranes (Fig. 4) are very similar to those previously
reported for brain homogenates of 8.1 mM (carvedilol) and
0.3 mM (BM-910228) in a Fe21-ascorbate-induced lipid
peroxidation model [6]. In our studies, ADP and Fe were
chosen as lipid peroxidation inducers, because increased
concentrations of these compounds were reported in isch-
emia and postischemia reperfusion situations [18].
Our results clearly demonstrate that the peroxidation of
mitochondrial membrane lipids induced by ADP/Fe21 dis-
plays a concentration-dependent inhibition by carvedilol
and BM-910228. The antiperoxidative effects of carvedilol
and BM-910228 were different, with a complete peroxida-
tive inhibition at 10- and 0.5-mM concentrations, respec-
tively. The inhibitory effects of carvedilol and BM-910228
were much greater than those of a-tocopheryl succinate
(IC50 5 125 mM) and Trolox C (IC50 5 31 mM). Previous
studies have demonstrated that a-tocopherol and Trolox, a
water-soluble analog of a-tocopherol, may attenuate myo-
cardial injury from ischemia and reperfusion [44]. It is
Fig. 6. Effects of carvedilol and BM-910228 on mitochondrial transmem-
brane potential fluctuations associated with respiration and the phospho-
rylative cycle. Rat heart mitochondria (1 mg) in 1 mL of medium consist-
ing of 130 mM sucrose, 50 mM KCl, 2.5 mM KH2PO4, 5 mM HEPES (pH
7.4), at 25°, supplemented with 3 mM rotenone and 3 mM TPP1, were
energized with 8 mM succinate after a 2-min incubation. Addition of 0.25
mM ADP induced the state 3 condition (depolarization) followed by
repolarization. Concentrations (in mM) of tested compounds are indicated
on traces. The traces represent typical recordings from several (4–5)
experiments, each performed in duplicate.
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noteworthy that, in our study, carvedilol showed an antiox-
idant activity in rat heart mitochondria 20-fold greater than
that of a-tocopheryl succinate, while its metabolite BM-
910228 displayed an exceptional antiperoxidative action 27
times stronger than that of carvedilol (Fig. 4).
The evaluation of mitochondrial transmembrane electric
potential (DC) is most important in studies of mitochondrial
functions, since it represents the main component of the
electrochemical gradient generated by mitochondrial respi-
ration and accounts for more than 90% of the total available
energy [45]. The energetic efficiency of mitochondria is
clearly linked to the intactness of the inner mitochondrial
membrane. It has been shown that lipid peroxidation pro-
cesses correlate with alterations in the integrity of mito-
chondrial membranes, which cause perturbation of mito-
chondrial functions [46]. As expected, the induction of lipid
peroxidation with ADP/Fe21 brought about a drop in the
DC generated by mitochondrial respiration. Carvedilol and
BM-910228 suppressed the de-energization of mitochondria
at the concentration range shown to inhibit mitochondrial
membrane lipid peroxidation. These data clearly indicate
that carvedilol and its metabolite may contribute to the
preservation of mitochondrial function in pathological situ-
ations associated with cellular oxidative stress.
It is of utmost importance that neither carvedilol nor
BM-910228 induced any toxic effects on mitochondrial
function, since mitochondrial phosphorylation efficiency is
not affected by the concentration range of the compounds
that inhibit the peroxidation of mitochondrial membranes,
as was shown by the lack of significant alterations in the
respiratory control index and the ADP/O ratios of mitochon-
dria. To confirm the non-toxic nature of the compounds, we
further evaluated the DC fluctuations associated with mito-
chondrial energization and the phosphorylation cycle. In-
deed, the results show that there were no significant alter-
ations in the profile of DC fluctuations, with a single
exception: carvedilol slightly, but consistently, depressed
the DC generated by respiration. This is a striking obser-
vation in view of the fact that the compound does not
compromise the mitochondrial phosphorylation capacity.
Carvedilol’s depressive effect might be related to the induc-
tion of the permeabilization of the inner mitochondrial
membrane to protons. This was confirmed using the top-
down approach of Brand [47]; non-phosphorylating mito-
chondria were titrated with malonate (an inhibitor of the
respiratory chain) and the respiratory activities and corre-
sponding DC changes were determined simultaneously
(data not shown). We concluded that carvedilol induces a
slight membranar proton leak for the concentration range
used (up to 10 mM). This effect may be related to a mild
protonophoretic action of the compound. Recent evidence
suggests that mild uncoupling of mitochondria (depression
of DC) may be an effective mechanism to reduce mitochon-
drial ROS without seriously compromising cellular energet-
ics [48]. Therefore, the slight depressive effect of carvedilol
on mitochondrial DC might have a protective effect per se
on the cell. In fact, it was shown previously that mitochon-
dria greatly reduce the production of ROS when the DC is
only slightly decreased by using very low concentrations of
a protonophore [49]. Thus, this mechanism may be added to
other known effective protective mechanisms of carvedilol,
such as superoxide and hydroxyl scavenger activity and
chain-breaking activity [2–6].
The aim of our investigation was to study the possibility
of a direct protective effect of carvedilol and its metabolite
on isolated heart mitochondria under oxidative stress con-
ditions. Our results indicate that relatively low concentra-
tions of carvedilol and BM-910228 protect mitochondria
from the deleterious action of membrane lipid peroxidation.
Most importantly, we also show that both compounds in the
concentration range showing their antioxidant action do not
affect mitochondrial bioenergetics.
Lipid peroxidation inhibition achieved in vitro by carve-
dilol occurs at micromolar levels, whereas the plasma peak
concentration of carvedilol in humans has been reported to
be 0.3 mM after an oral dose of 50 mg [50]. Therefore, the
results reported in our study would be relevant only if some
type of concentration process exists. In fact, carvedilol is a
highly lipophilic compound with a partition coefficient (log
P octanol-H2O) of 3.4, which is similar to that of propran-
olol [6]. It is meaningful that the accumulation of propran-
olol in Purkinje fibers and platelets reached concentrations
up to 30- to 40-fold higher than plasma concentration [51].
Although we do not know the exact levels of carvedilol in
lipid membranes, the large distribution volume of carvedilol
(132 L) in humans indicates that the drug is extensively
distributed to the tissue [52]. Therefore, it is quite conceiv-
able that an effective level of carvedilol capable of inhibit-
ing lipid peroxidation may be attained in vivo, which gives
clinical relevance to carvedilol’s antioxidant effect.
In conclusion, the antioxidant properties of carvedilol
may contribute to the cardioprotective effect of the com-
pound, namely through the preservation of mitochondrial
functions whose importance in the pathogenesis of myocar-
dial ischemia/reperfusion injury is clearly documented. Ad-
ditionally, its hydroxylated analog BM-910228, one of the
most important metabolites found in humans and one pos-
sessing superior antioxidant activity, may significantly con-
tribute to the therapeutic effects of carvedilol.
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